CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will present an update on Company progress at two upcoming conferences in March using a virtual platform.
- Ian Somaiya, Chief Financial Officer of TCR 2 Therapeutics, will present corporate presentation at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021 at 7:00am ET
- Ian Somaiya, Chief Financial Officer of TCR 2 Therapeutics, and Robert Hofmeister, Ph.D., Chief Scientific Officer of TCR 2 Therapeutics, will participate in a fireside chat at the 33rd Annual Roth Conference on March 17, 2021 at 11:00am ET
A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com . An archived replay will be available for at least 30 days following the presentation.
About TCR 2 Therapeutics
TCR 2 Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR 2 ’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC ® -T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR 2 , please visit www.tcr2.com.
Investor and Media Contact:
Carl Mauch
Director, Investor Relations and Corporate Communications
TCR 2 Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com